Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
P/E ratio for Tarsus Pharmaceuticals, Inc. (TARS)
P/E ratio as of 2023: -4.38
According to Tarsus Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -4.38. At the end of 2022 the company had a P/E ratio of -5.81.
P/E ratio history for Tarsus Pharmaceuticals, Inc. from 2018 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -4.38 |
| 2022 | -5.81 |
| 2021 | -33.45 |
| 2020 | -31.33 |
| 2019 | -85.97 |
| 2018 | -66.86 |